Literature DB >> 15770410

Combined effect of an ACE inhibitor, perindopril, and interferon on liver fibrosis markers in patients with chronic hepatitis C.

Hitoshi Yoshiji, Ryuichi Noguchi, Hiroshi Fukui.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15770410     DOI： 10.1007/s00535-004-1523-6

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN： 0944-1174            Impact factor:   7.527


× No keyword cloud information.
  9 in total

1.  The effects of angiotensin blocking agents on the progression of liver fibrosis in the HALT-C Trial cohort.

Authors:  Barham K Abu Dayyeh; May Yang; Jules L Dienstag; Raymond T Chung
Journal:  Dig Dis Sci       Date:  2010-12-07       Impact factor: 3.199

2.  Interferon augments the anti-fibrotic activity of an angiotensin-converting enzyme inhibitor in patients with refractory chronic hepatitis C.

Authors:  Hitoshi Yoshiji; Ryuichi Noguchi; Hideyuki Kojima; Yasuhide Ikenaka; Mitsuteru Kitade; Kosuke Kaji; Masahito Uemura; Junichi Yamao; Masao Fujimoto; Masaharu Yamazaki; Masahisa Toyohara; Akira Mitoro; Hiroshi Fukui
Journal:  World J Gastroenterol       Date:  2006-11-14       Impact factor: 5.742

3.  Effect of propranolol on the splanchnic and peripheral renin angiotensin system in cirrhotic patients.

Authors:  Walkíria Wingester Vilas-Boas; Antônio Ribeiro-Oliveira; Renata da Cunha Ribeiro; Renata Lúcia Pereira Vieira; Jerusa Almeida; Ana Paula Nadu; Ana Cristina Simões e Silva; Robson Augusto Souza Santos
Journal:  World J Gastroenterol       Date:  2008-11-28       Impact factor: 5.742

4.  The effect of angiotensin-blocking agents on liver fibrosis in patients with hepatitis C.

Authors:  Kathleen E Corey; Nirali Shah; Joseph Misdraji; Barham K Abu Dayyeh; Hui Zheng; Atul K Bhan; Raymond T Chung
Journal:  Liver Int       Date:  2009-02-09       Impact factor: 5.828

5.  Moexipril for treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid.

Authors:  Phunchai Charatcharoenwitthaya; Jayant A Talwalkar; Paul Angulo; Andrea A Gossard; Jill C Keach; Janice L Petz; Roberta A Jorgensen; Keith D Lindor
Journal:  Dig Dis Sci       Date:  2009-03-03       Impact factor: 3.199

6.  Hepatocellular carcinoma chemoprevention by targeting the angiotensin-converting enzyme and EGFR transactivation.

Authors:  Emilie Crouchet; Shen Li; Mozhdeh Sojoodi; Simonetta Bandiera; Naoto Fujiwara; Hussein El Saghire; Shijia Zhu; Tongqi Qian; Fahmida Akter Rasha; Fabio Del Zompo; Stephen C Barrett; Eugénie Schaeffer; Marine A Oudot; Clara Ponsolles; Sarah C Durand; Sarani Ghoshal; Gunisha Arora; Fabio Giannone; Raymond T Chung; Nevena Slovic; Nicolaas Van Renne; Emanuele Felli; Patrick Pessaux; Joachim Lupberger; Nathalie Pochet; Catherine Schuster; Kenneth K Tanabe; Yujin Hoshida; Bryan C Fuchs; Thomas F Baumert
Journal:  JCI Insight       Date:  2022-07-08

7.  MicroRNA-21 Mediates Angiotensin II-Induced Liver Fibrosis by Activating NLRP3 Inflammasome/IL-1β Axis via Targeting Smad7 and Spry1.

Authors:  Zuo-Wei Ning; Xiao-Ying Luo; Guo-Zhen Wang; Yang Li; Miao-Xia Pan; Ren-Qiang Yang; Xu-Guang Ling; Shan Huang; Xiao-Xin Ma; Si-Yi Jin; Dan Wang; Xu Li
Journal:  Antioxid Redox Signal       Date:  2016-09-12       Impact factor: 8.401

8.  Therapeutic effect of renin angiotensin system inhibitors on liver fibrosis.

Authors:  Qianqian Zhu; Na Li; Fang Li; Zhihua Zhou; Qunying Han; Yi Lv; Jiao Sang; Zhengwen Liu
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2016-03-23       Impact factor: 1.636

Review 9.  Liver disease and the renin-angiotensin system: recent discoveries and clinical implications.

Authors:  John S Lubel; Chandana B Herath; Louise M Burrell; Peter W Angus
Journal:  J Gastroenterol Hepatol       Date:  2008-06-28       Impact factor: 4.029
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.